Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5655 - Differences in outcome according to chemotherapy backbone and maintenance treatment in HER2 positive metastatic gastric cancer (GC) or gastroesophageal junction (GEJ).

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cytotoxic Therapy

Tumour Site

Gastric Cancer

Presenters

Nieves Martinez Lago

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

N. Martinez Lago1, S. Candamio Folgar2, C. Grande Ventura3, M. Salgado Fernandez4, J. De la Camara Gomez5, J.C. Méndez Méndez6, D. Arias Ron4, F. Vazquez7, M. Reboredo Lopez1, Y. Vidal Ínsua2, B. Graña Suarez1, M. Jorge Fernandez3, M.E. Brozos Vazquez8, M.L. Pellon Augusto5, J. Prato Varela1, P. Gonzalez Villarroel3, A. Fernandez Montes9

Author affiliations

  • 1 Medical Oncology, Hospital Universitario a Coruna, 15006 - A Coruna/ES
  • 2 Medical Oncology Department, University Clinical Hospital of Santiago de Compostela, 15706 - Santiago de Compostela/ES
  • 3 Medical Oncology, Hospital Universitario Alvaro Cunqueiro, Vigo/ES
  • 4 Medical Oncology Department, Complejo Hospitalario De Ourense, 32005 - Ourense/ES
  • 5 Medical Oncology Department, Complexo Hospitalario Universitario de Ferrol, Ferrol/ES
  • 6 Medical Oncology Department, Centro Oncológico de Galicia, 15009 - A Coruña/ES
  • 7 Medical Oncology Department, Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, 15706 - Santiago de Compostela/ES
  • 8 Medical Oncology, Complexo Hospitalario Universitario de Santiago, Santiago de Compostela/ES
  • 9 Medical Oncology, Complexo Hospitalario Universitario de Ourense, Ourense/ES

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5655

Background

Although the TOGA study used cisplatin plus capecitabine (XP) or fluorouracil (FP), oxaliplatin schedules (CAPOX or FOLFOX) are commonly used. There is also a discrepancy in the no. of cycles and the maintenance treatment with trastuzumab (T).

Methods

We conducted an observational, retrospective, multicentric study of patients with metastatic HER2 GC or GEJ treated at 6 spanish hospitals belonging to Galician Research Group on Digestive Tumors (GITuD). Demographic, clinic and pathological data were retrospectively collected and correlated with overall survival (OS) and progression free survival (PFS).

Results

91 pts treated between May 2010 to January 2018 were recorded. Median age was 68 years (range 38-84 years), 74.7% were male, 39.6% GEJ location, 82.9% intestinal Lauren subtype, 64.5% well-moderate differentiated, 82.4% synchronous disease and 24.2% primary tumor resection. Median of metastatic locations was 2 (range 1-4). Chemotherapy backbone: FP 4.7%, XP 21.2%, CAPOX 37.6%, FOLFOX 36.5%. With a median follow up of 45.6 months, 85 pts were evaluable for efficacy. Median OS was 14.2 months (CI 95% 10.3-18.0 months) and median first line PFS was 8.9 months (CI 95% 7.7-10.1 months). Overall response rate 57.6% and disease control rate 78.8%. Median cycles of induction treatment were 6 (range 1-18). No PFS differences were found according to the platinum (p = 0.579) or fluropirimidine used (p = 0.955). Of 47 non-progressive patients after 6 months the majority received maintenance treatment for a median of 6.5 cycles (range2-77) with T +/- fluoropirimidine (21 and 16 pts) while 10 discontinued treatment. Post-induction PFS favors those who continued treatment with a PFS of 7.6 vs 5.0 months (p = 0.033), without differences between schemas (p = 0.890)). Primary tumor surgery (HR 0.380; p = 0.010), neutrophil to lymphocyte ratio < 5 (HR 0.461; p = 0.008), platelet to lymphocyte ratio <200 (HR 0.557; p = 0.030) were associated with prolonged OS.

Conclusions

Maintenance treatment with T has a benefit in terms of PFS even in patients who received T during induction. The practice of continuing the fluoropirimidine during maintenance doesńt appear to add any PFS benefit in our series.

Clinical trial identification

Legal entity responsible for the study

Galician Research Group on Digestive Tumors.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.